Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $126027.0.

  • Evoke Pharma's Interest Expenses changed 0.0% to $126027.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500001.0, marking a year-over-year decrease of 27.29%. This contributed to the annual value of $501370.0 for FY2024, which is 27.4% up from last year.
  • Per Evoke Pharma's latest filing, its Interest Expenses stood at $126027.0 for Q3 2025, which was down 0.0% from $124658.0 recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Interest Expenses peaked at $126028.0 during Q3 2023, and registered a low of $123288.0 during Q1 2022.
  • Moreover, its 5-year median value for Interest Expenses was $124658.0 (2021), whereas its average is $125020.7.
  • Its Interest Expenses has fluctuated over the past 5 years, first soared by 417789.98% in 2021, then plummeted by 109.9% in 2025.
  • Evoke Pharma's Interest Expenses (Quarter) stood at $126026.0 in 2021, then grew by 0.0% to $126027.0 in 2022, then changed by 0.0% to $126027.0 in 2023, then grew by 0.0% to $126028.0 in 2024, then dropped by 0.0% to $126027.0 in 2025.
  • Its Interest Expenses stands at $126027.0 for Q3 2025, versus $124658.0 for Q2 2025 and $123288.0 for Q1 2025.